Prazosin

Abstract

PRAZOSIN (l-[4-amino-6,7-dimethoxy-2-quinazoline]-4-[2-furoyl]-piperazine) (Fig. 1), the first of a new class of antihypertensive agents, was released for clinical use in the United States in 1976.¹ Although it has been used effectively as a single agent, its widest application is in combination with other drugs in the therapy of patients with chronic hypertension. Preliminary data suggest that prazosin may also have a role in the therapy of severe congestive heart failure by effecting a reduction in cardiac pre-load and after-load.Site and Mechanism of ActionPrazosin exerts its hypotensive action by reducing peripheral vascular resistance as a consequence of blockade of vascular . . .